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the last 4 weeks?” In many languages a literal translation
would have been unclear and so the question was re-
placed by “how much of the time. . . .” Patient testing
showed different reactions to the instrument across coun-
tries and made it clear that terms such as “intercourse,”
“erection,” or “ejaculation” were not always understood
and required explanation. Prior to use in an international
trial, rigorous cultural adaptation was essential to pro-
duce cross-culturally valid language versions. Psychomet-
ric testing will be important to ensure similar relation-
ships among scales across countries. The comparison of
answer patterns across countries will clarify whether peo-
ple with similar health give equivalent answers.
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OBJECTIVE: To evaluate the economic effect of using
risperidone in nursing home residents with documented
behavioral and psychological signs and symptoms of de-
mentia (BPSSD).
METHODS: Based on 1995 data from a large nursing
home database, the average annual incremental cost of
care due to BPSSD was calculated for three diagnosis
groups (All Diagnoses, All Dementia, and Non-Demen-
tia). These costs, in 1997 US dollars, included increased
reimbursement resulting from transition to a higher level
of care and more frequent physician visits due to BPSSD.
These were compared with the cost of 1 mg per day ris-
peridone therapy.
RESULTS: BPSSD was documented in 13.5% of all nurs-
ing home residents—in 20% of those with dementia and
in 11% in those without dementia. The annual cost of
risperidone was estimated at $101, $148, and $85, re-
spectively, per patient in each group. The BD-related
costs considering all patients, regardless of behavioral
status, were $245, $383, and $195, respectively, per resi-
dent in each group. Risperidone was estimated to break
even if 42% of BPSSD-related transitions to a higher level
of care were prevented among all patients, 39% if only
demented patients are considered, and 44% for those
without dementia. With higher effectiveness, treatment
with risperidone would result in cost-savings. 
CONCLUSIONS: The use of risperidone in institutional-
ized patients with BPSSD should provide not only sub-
stantial relief of what can be a difficult-to-manage situa-
tion but also a favorable economic effect.
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OBJECTIVES: The annual prevalence and annual inci-
dence of the diagnosis of multiple sclerosis (MS) in the UK
were determined, together with the therapies employed,
the associated costs, and the referrals to secondary care.
METHODS: This study used UKPCD, which contains
longitudinal records of nearly 2 million patients. Data are
captured daily from general practitioners who use the
AAH Meditel System 5 software as part of their standard
record keeping. Patients were selected according to the
primary care coding system, “Read,” (entered as a prob-
lem or problem-linked note code), from June 1997 to
June 1998. Therapies, prescription costs, and referrals
were extracted from these patients’ records.
RESULTS: The annual prevalence of MS was 62/100,000
(95% CI 58–66); the annual incidence was 7/100,000
(95% CI 6–8). A comparison of all therapies used to
manage MS patients showed apparent differences between
prevalent and incident patients, except in antidepressants
(36% both groups). Non-narcotic analgesics were pre-
scribed for 45% of prevalent patients and 32% of incident
patients. When therapy for prevalent patients was linked
to the Read code for MS, 33% of patients were prescribed
central muscle relaxants and 24% antidepressants. The
cost to the community for all prescribed products in the
study year was £159,508. The majority of note referrals
for both prevalent and incident patients was for neurolo-
gist care (20% and 40%) and physiotherapy (12% and
14%), respectively.
CONCLUSION: This study is an example of the use of an
automated, observational, primary care database such as
MediPlus in pharmacoeconomic and outcomes research.
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OBJECTIVE: Patients report in general to be dissatisfied
with headache treatment. A disease management pro-
gram was developed to improve the quality of headache
treatment of a general sick fund–insured population.
METHOD: Employees at a ship-building site (n  1996)
and their families were asked to fill in questionnaires if
they suffered from headache: the Short-Form 36, the Kiel
